Company Insights

OLK customer relationships

Explore interactive graphBrowse insights index
OLK customer relationship map

Olink (OLK): Commercial footprint and why its customer relationships matter for valuation

Olink monetizes a proprietary proteomics platform by selling instruments, consumable assays and certified service access to academic centers, biopharma and commercial labs; revenue combines product sales, service agreements and a growing certified-lab network that drives recurring assay orders and scale advantages. Investors should view Olink as a platform business whose valuation depends on adoption across high-value research partners, the depth of its certified-service network, and the company’s ability to convert research use into sustained assay volumes and service revenue. For an institutional briefing on customer intelligence and counterparty mapping, visit Null Exposure.

How Olink sells: platform, assays and a certified-lab ecosystem

Olink’s commercial model has three revenue levers: hardware sales of the Explore/Signature/Signature systems, recurring assay and consumable purchases tied to those platforms, and fees or volume agreements with certified service providers that run assays for third parties. The business shows high gross margins at the assay level (gross profit $94.5M on $170.9M revenue TTM) but negative operating margins as Olink invests in platform rollout and market expansion (operating margin TTM -86.8%). These financials indicate a company in scale-up mode: capitalizing on proprietary chemistry and certification to lock in long-term assay volume while carrying an operating loss during growth.

What the customer map reveals about risk and runway

The customer list assembles leading academic centers, commercial CROs and biorepositories—an ideal mix for validating platform utility, accelerating adoption and generating high-volume work. That breadth reduces single-customer concentration risk while the presence of major partners and networks (UK Biobank, large CROs and university medical centers) signals technical validation and pathway-to-revenue for large cohort studies. For deeper institutional research and counterparty diligence, see Null Exposure.

Customer relationships (complete list from the available sources)

Below I list every named relationship in the reviewed results with a concise one-line summary and source reference.

  • Erasmus Medical Center — The Human Genomics Facility at Erasmus adopted Olink technology and became the first Olink Explore certified laboratory in the Netherlands (GlobeNewswire, June 2022).
  • Discovery Life Sciences — Discovery installed the largest commercial Olink platform in the Americas outside of Olink itself to operate as a certified service provider for Proximity Extension Assay (PR Newswire, FY2022).
  • Thermo Fisher Scientific Inc — Baker McKenzie advised Olink in merger-control matters related to its sale to Thermo Fisher, indicating Thermo Fisher’s strategic interest in acquiring Olink’s assets (Baker McKenzie newsroom, FY2024).
  • BioXpedia — Named as a member of Olink’s global certified laboratory network in Olink’s global network announcement (Yahoo Finance press release, FY2024).
  • CheckImmune — Included as a member of the Olink-certified network announced by the company (Yahoo Finance press release, FY2024).
  • Core Facility Metabolomics and Proteomics, Helmholtz Munich — Listed among the inaugural global network of certified Olink laboratories (Yahoo Finance press release, FY2024).
  • CRLB-GMEL, Hamilton Health Sciences — Appears on Olink’s certified-provider roster in the company announcement (Yahoo Finance press release, FY2024).
  • Firalis Molecular Precision SA — Cited as a certified network member in Olink’s public announcement (Yahoo Finance press release, FY2024).
  • GENEWIZ from Azenta Life Sciences — Included in the published list of certified labs partnering with Olink (Yahoo Finance press release, FY2024).
  • Immune Assessment Laboratory, Dana-Farber Cancer Institute — Named in Olink’s global network as a certified lab using the platform (Yahoo Finance press release, FY2024).
  • Immune Monitoring and Cancer Omics Labs, OHSU Knight Cancer Institute — Identified as a certified customer in Olink’s global network release (Yahoo Finance press release, FY2024).
  • LIFE & BRAIN — Listed among Olink’s certified global partners in the company announcement (Yahoo Finance press release, FY2024).
  • LuminoDx — Included in Olink’s certified laboratory network list (Yahoo Finance press release, FY2024).
  • Microcoat — Named as a member of the Olink-certified lab network (Yahoo Finance press release, FY2024).
  • NBCC-HTS (Sinai Health System) — Appears on Olink’s published roster of certified providers (Yahoo Finance press release, FY2024).
  • NovogeneAIT Genomics — Included in Olink’s global network announcement (Yahoo Finance press release, FY2024).
  • Protavio — Cited among certified Olink labs in the public release (Yahoo Finance press release, FY2024).
  • Psomagen Inc — Named in the Olink-certified network announcement (Yahoo Finance press release, FY2024).
  • Randox — Included as a certified lab partner in Olink’s list (Yahoo Finance press release, FY2024).
  • Sampled — Listed as a member of the Olink-certified global network (Yahoo Finance press release, FY2024).
  • Sequanta Technologies — Appears in Olink’s published list of certified service providers (Yahoo Finance press release, FY2024).
  • Sirona Dx — Included among the certified network members in Olink’s announcement (Yahoo Finance press release, FY2024).
  • Source BioScience — Named as a certified Olink laboratory in the company’s global network release (Yahoo Finance press release, FY2024).
  • Svar Life Science — Appears on the certified-provider roster published by Olink (Yahoo Finance press release, FY2024).
  • Swiss Institute of Allergy and Asthma Research — Listed among certified partners in Olink’s public announcement (Yahoo Finance press release, FY2024).
  • Universidad CEU San Pablo, Institute of Molecular Applied Medicine Nemesio Díez (IMMA-ND) — Included as a certified lab partner in Olink’s global network announcement (Yahoo Finance press release, FY2024).
  • Vanderbilt University Medical Center — Named as a certified Olink partner in the company’s network rollout (Yahoo Finance press release, FY2024).
  • WuXi AppTec — Listed among Olink’s certified service providers in the published network (Yahoo Finance press release, FY2024).
  • UK Biobank — Used Olink Explore 1536 at scale for pQTL mapping across 54,306 participants in a major genetic regulation study (TechnologyNetworks report, FY2022).
  • AssayGate — Included in Olink’s global certified-lab announcement (Yahoo Finance press release, FY2024).
  • Australian Genome Research Facility — Listed as a member of the Olink-certified network in the public release (Yahoo Finance press release, FY2024).
  • Radboud UMC / Radboudumc — Radboud reports using Olink platforms (Signature and Explore) for proteomics in internal and collaborative studies, citing reduced sample volumes and cost-per-sample benefits (GlobeNewswire release and Olink press, FY2021–FY2022).
  • Fulgent Genetics — Appears on Olink’s published list of certified network members (Yahoo Finance press release, FY2024).

Operating-model signals and commercial constraints (company-level)

There are no explicit contractual constraints provided in the reviewed material. From the customer map and financials, infer the following company-level signals:

  • Contracting posture: Olink uses a mix of hardware sales and certification agreements to create recurring revenue through consumable assays and certified-service referrals; relationships are structured to encourage long-term assay volume.
  • Concentration: The certified-lab network spans academic centers, CROs and commercial labs, indicating low counterparty concentration risk at the top-line level.
  • Criticality: Multiple large cohort studies and major research centers rely on Olink’s platform for proteomics; the technology is mission-critical for high-throughput proteomic mapping in genetics and biomarker programs.
  • Maturity: The presence of flagship customers (UK Biobank, major university hospitals) signals commercial validation, but negative operating margins show the company is still in active growth investment mode.

Investment takeaways and risk framing

  • Positive: A broad certified-provider network and adoption by flagship institutions provide tangible pathways to recurring assay revenue and large-scale study contracts; gross profitability on assays gives leverage as volumes grow.
  • Negative: Operating losses and a high EV/revenue multiple reflect aggressive growth expectations; integration or consolidation risk exists following Thermo Fisher’s stated interest.
  • Catalysts to watch: expansion of certified-lab coverage in Asia and the Americas, conversion of large cohort studies into repeat orders, and any strategic transaction that accelerates distribution or reduces instrument unit economics.

For curated counterparty due diligence, investor memos and relationship scoring built from filings and press releases, visit Null Exposure.

Final note for analysts

Olink’s revenue model is platform-driven with recurring economics, validated by a wide roster of academic and commercial partners; the key valuation debate is whether assay demand scales fast enough to justify current multiples while the company transitions to operating profitability. For tailored customer-risk reports and institutional-grade relationship maps, see Null Exposure.